These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12637894)

  • 41. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
    Buellesfeld L; Grube E
    Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis.
    Lee CW; Park CB; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):104-8. PubMed ID: 17139669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
    Lau KW; Johan A; Sigwart U; Hung JS
    Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of stent design and coatings on restenosis and thrombosis.
    Hara H; Nakamura M; Palmaz JC; Schwartz RS
    Adv Drug Deliv Rev; 2006 Jun; 58(3):377-86. PubMed ID: 16650911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preventing restenosis with stent drug coatings.
    Belardi J
    J Invasive Cardiol; 2002 Sep; 14(9):576-82. PubMed ID: 12369563
    [No Abstract]   [Full Text] [Related]  

  • 47. Lessons from the E-SIRIUS trial.
    Schofer J
    Ital Heart J; 2004 Jan; 5(1):1-2. PubMed ID: 15080572
    [No Abstract]   [Full Text] [Related]  

  • 48. Taxol-based eluting stents from theory to human validation: clinical and intravascular ultrasound observations.
    Sonoda S; Honda Y; Kataoka T; Bonneau HN; Sudhir K; Yock PG; Mintz GS; Fitzgerald PJ
    J Invasive Cardiol; 2003 Mar; 15(3):109-14. PubMed ID: 12612382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is zero enough?
    Gonschior P
    J Invasive Cardiol; 2002 Sep; 14(9):514. PubMed ID: 12205349
    [No Abstract]   [Full Text] [Related]  

  • 50. Correct optimization of drug-eluting stents should be regarded in the same light as POETry.
    Gerber R; Colombo A
    Am J Cardiol; 2008 Oct; 102(8):1113-4. PubMed ID: 18929719
    [No Abstract]   [Full Text] [Related]  

  • 51. Use of drug eluting stents: expert consensus of the French Society of Cardiology.
    Danchin N; Blanchard D; Chevalier B; Eltchaninoff H; Ferrières J; Steg PG; Machecourt J
    Arch Cardiovasc Dis; 2008 Mar; 101(3):190-3. PubMed ID: 18477947
    [No Abstract]   [Full Text] [Related]  

  • 52. Coated stents for the prevention of restenosis: Part I.
    Babapulle MN; Eisenberg MJ
    Circulation; 2002 Nov; 106(21):2734-40. PubMed ID: 12438301
    [No Abstract]   [Full Text] [Related]  

  • 53. Surface modification of stents for improving biocompatibility.
    al-Lamee K
    Med Device Technol; 2000; 11(1):12-6, 18, 20. PubMed ID: 10915480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct comparisons, new technologies highlight DES symposium.
    Kahn J
    J Interv Cardiol; 2005 Aug; 18(4):295-8. PubMed ID: 16115162
    [No Abstract]   [Full Text] [Related]  

  • 55. Local Anti-miR Delivery: The Latest in the Arsenal of Drug-Eluting Stents.
    Moore KJ; Rayner KJ
    Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):1905-6. PubMed ID: 26310808
    [No Abstract]   [Full Text] [Related]  

  • 56. Ask the doctors. Are drug-coated stents living up to potential that you and other publications wrote about a year or so ago?
    Heart Advis; 2004 Dec; 7(12):8. PubMed ID: 15782433
    [No Abstract]   [Full Text] [Related]  

  • 57. Restenosis: do we need to understand it to treat it?
    Faxon D
    J Am Coll Cardiol; 2002 Dec; 40(12):2090-1. PubMed ID: 12505218
    [No Abstract]   [Full Text] [Related]  

  • 58. Drug-eluting stents.
    Med Lett Drugs Ther; 2003 Mar; 45(1152):23-4. PubMed ID: 12637894
    [No Abstract]   [Full Text] [Related]  

  • 59. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug-eluting stents for the prevention of restenosis: Standing the test of time.
    Carter AJ
    Catheter Cardiovasc Interv; 2002 Sep; 57(1):69-71. PubMed ID: 12203932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.